2023, A Landmark Year in Biomedical Research; A Turning Point in Medical History

Document Type : Letter to The Editor

Authors

Department of Regenerative Medicine, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran

Abstract

The rapid development of knowledge on healthy nutrition, and hygiene practices, as well as the advent of antibiotics
and vaccines, has led to increased life expectancy in the recent century. The extended lifespan has brought new
challenges for healthcare professionals, including the management of chronic degenerative diseases, malignancies,
and autoimmune disorders. Advanced therapeutic medicinal products (ATMPs) have emerged as a promising frontier
alongside conventional therapeutic modalities, offering innovative solutions through cell-based therapies, gene therapy,
and tissue engineering. Recent years have witnessed remarkable advancements in regenerative medicine and the
launching of innovative ATMPs. Numerous ATMPs have been registered and approved by regulatory agencies for the
management of different diseases in 2023. The approval of groundbreaking therapies around the world has made 2023
an exceptional year. Novel ATMPs and the development of artificial intelligence (AI) in 2023 will pave the way for the
integration of ATMPs and advanced technologies in personalized medicine, early diagnosis, and targeted treatments.

Keywords

Main Subjects

References

  1. Rosen G. A history of public health. Johns Hopkins University Press; 2015.
  2. Partridge L, Deelen J, Slagboom PE. Facing up to the global challenges of ageing. Nature. 2018; 561(7721): 45-56.
  3. Ramezankhani R, Torabi S, Minaei N, Madani H, Rezaeiani S, Hassani SN, et al. Two decades of global progress in authorized advanced therapy medicinal products: an emerging revolution in therapeutic strategies. Front Cell Dev Biol. 2020; 8: 547653.
  4. Piemonti L, Scholz H, de Jongh D, Kerr-Conte J, van Apeldoorn A, Shaw JAM, et al. The relevance of advanced therapy medicinal products in the field of transplantation and the need for academic research access: overcoming bottlenecks and claiming a new time. Transpl Int. 2023; 36: 11633.
  5. Diaz-Solano D, Sadri B, Peshkova M, Shpichka A, Smirnova O, Shams R, et al. Advanced therapeutic medicinal products in bone and cartilage defects. Curr Rev Clin Exp Pharmacol. 2024 (ahead of print).
  6. FDA. Approved cellular and gene therapy products. Available from: https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy- products/approved-cellular-and-gene-therapy-products (04 Mar 2024).
  7. FDA. FDA approves first gene therapies to treat patients with sickle cell disease 12/8/23. Available from: https://www.fda.gov/newsevents/ press-announcements/fda-approves-first-gene-therapiestreat- patients-sickle-cell-disease (04 Mar 2024).
  8. Frangoul H, Altshuler D, Cappellini MD, Chen YS, Domm J, Eustace BK, et al. CRISPR-Cas9 gene editing for sickle cell disease and β-thalassemia. N Engl J Med. 2021; 384(3): 252-260.
  9. Sheridan C. The world’s first CRISPR therapy is approved: who will receive it? Nat Biotechnol. 2024; 42(1): 3-4.
  10. Sharma A, Boelens JJ, Cancio M, Hankins JS, Bhad P, Azizy M, et al. CRISPR-Cas9 editing of the HBG1 and HBG2 promoters to treat sickle cell disease. N Engl J Med. 2023; 389(9): 820-832.
  11. Shahrbaf MA, Ataei Fashtami L, Vosough M. The first live-cell based product in the Iranian drug list; ReColorCell®. Cell J. 2023; 25(3): 212-214.
  12. Orouji Z, Bajouri A, Ghasemi M, Mohammadi P, Fallah N, Shahbazi A, et al. A single-arm open-label clinical trial of autologous epidermal cell transplantation for stable vitiligo: a 30-month follow-up. J Dermatol Sci. 2018; 89(1): 52-59.
  13. Khodadadi L, Shafieyan S, Sotoudeh M, Dizaj AV, Shahverdi A, Aghdami N, et al. Intraepidermal injection of dissociated epidermal cell suspension improves vitiligo. Arch Dermatol Res. 2010; 302(8): 593-599.
  14. Cheng K, Guo Q, He Y, Lu Y, Gu S, Wu H. Exploring the potential of GPT-4 in biomedical engineering: the dawn of a new era. Ann Biomed Eng. 2023; 51(8): 1645-1653.

Files

Share

How to cite

Statistics